Some antidiabetic drugs that have shown promising results in terms of atrial remodeling and AF prevention or treatment include metformin, thiazolidinediones (TZDs), sodium-glucose co-transporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors [51,52]. Here, DPP4 is linked to atrial fibrillation.